A yearlong study of older adults with cognitive decline in Japan found that drinking matcha green tea improved participants’ ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs. By Gina Kolata and Rebecca Robbins A daily pill may be as ...

The jab averse can now rejoice! Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.

Forget injections. A new drug promises to be just as effective as Ozempic — but is taken as a daily pill. Called orforglipron, the results of a new clinical trial announced Thursday by ...

Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...

"The red pill is like, 'I see the truth.' It’s a call to action by the manosphere,” Adam, played by Amari Bacchus, says in the show about an Instagram comment. “She’s saying he’s an ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered as a once-daily oral pill. The ACHIEVE-1 trial ...

New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 diabetes as injectable GLP-1 drugs. Drugmaker Eli Lilly said that in Phase 3 ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks ...

It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions. The pill form could expand access and reduce costs compared with injectable GLP-1 drugs. The move ...